Gb Sciences INC 10-Q quarterly reports

GB Sciences reported its first revenue from a new licensing agreement in Q3 2025, alongside reduced operating losses, but continues to face substantial doubt about its ability to continue as a going concern due to significant accumulated deficit and liquidity challenges.

GB Sciences reports its second quarter results for fiscal year 2025, highlighting ongoing drug development efforts and expansion of its intellectual property portfolio.

GB Sciences reports a net loss for the quarter ended June 30, 2024, while continuing to advance its drug development programs and intellectual property portfolio.

GB Sciences, a biopharmaceutical company, released its third quarter 2024 results, showcasing advancements in its drug development programs and intellectual property portfolio, while also noting ongoing financial challenges.